Literature DB >> 11668242

A mathematical model of axillary lymph node involvement considering lymph node size in patients with breast cancer.

T Suzuma1, T Sakurai, G Yoshimura, T Umemura, T Tamaki, Y Naito.   

Abstract

BACKGROUND: Surgical sampling for assessing axillary status has not been considered as a well defined surgical procedure. We have reported that MRI is a good instrument for assessing lymph node size and identifying lymph node position. We also developed a mathematical model that takes into consideration the size of axillary lymph nodes, and retrospectively determined the number and size of the axillary lymph nodes that need to be sampled from level I-II to achieve a greater than 90% probability of metastasis detection after surgical sampling, with the future aim of using MR-axillography to assess lymph node size.
METHODS: One thousand nine hundred and thirty four lymph nodes from 102 level I-II dissections performed on T1 and T2 breast cancer patients with nodal metastases were examined histologically and the greatest long-axis dimension on histologic slides was measured.
RESULTS: This model permitted determination of the cutoff level necessary for an expected probability of detection of metastasis of over 90%. The cutoff level, regardless of tumor size, is a maximum of 6 nodes removed from level I-II in which the greatest long-axis measurement is greater than or equal to 6 mm. The cutoff level in patients with macrometastatic nodes is a maximum of 3 or 4 nodes in which the long-axis dimensions are greater than or equal to 9 or 7 mm, respectively, removed from level I-II.
CONCLUSIONS: This model showed that surgical sampling on the basis of lymph node size might have good potential to detect lymph nodes metastases.

Entities:  

Mesh:

Year:  2001        PMID: 11668242     DOI: 10.1007/bf02967510

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  3 in total

1.  Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054.

Authors:  Dangshe Ma; Jessica R Kirshner; Richard Tavaré; Makenzie Danton; Jason T Giurleo; Sosina Makonnen; Carlos Hickey; Tomas C Arnold; Marcus P Kelly; Fanny Fredriksson; Karina Bruestle; Aynur Hermann; Erica Ullman; Kurt H Edelmann; Terra Potocky; Drew Dudgeon; Nikunj B Bhatt; Mikhail Doubrovin; Thomas Barry; Christos A Kyratsous; Cagan Gurer; Naxin Tu; Hans Gartner; Andrew Murphy; Lynn E Macdonald; Jon Popke; Akiva Mintz; Adam Griesemer; William C Olson; Gavin Thurston
Journal:  Cancer Immunol Res       Date:  2022-10-04       Impact factor: 12.020

2.  Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase.

Authors:  D Di Gioia; P Stieber; G P Schmidt; D Nagel; V Heinemann; A Baur-Melnyk
Journal:  Br J Cancer       Date:  2015-02-03       Impact factor: 7.640

3.  Diagnostic efficacy of whole-body diffusion-weighted imaging in the detection of tumour recurrence and metastasis by comparison with 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography or computed tomography in patients with gastrointestinal cancer.

Authors:  Jiaying Gong; Wuteng Cao; Zhanwen Zhang; Yanhong Deng; Liang Kang; Pan Zhu; Zhengjun Liu; Zhiyang Zhou
Journal:  Gastroenterol Rep (Oxf)       Date:  2014-11-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.